"Good Medicine" Qilu grabs more than 2 billion anti-ED market, rides on the third batch of harvester, "Sorafini" first imitation was approved, breaking the monopoly of the original research; Hengrui, Luo Xin, stone medicine...

Guide: The latest, consistent evaluation of the week dynamics! The third batch of collection will be opened on August 20, "collecting tickets" consistency evaluation work is still in an orderly process, as of August 14, CDE acceptance of the consistency evaluation acceptance number accumulated 2289 (535 varieties of 592 enterprises, according to supplementary applications, the same);
this week (August 7th to August 14th), five more varieties have been evaluated, and more than 1 billion large varieties are listed; Over-evaluation details of 5 varieties have been evaluated; 1 billion grade "Soralfini" first approved this week, 7 product regulations (5 varieties) through the consistency evaluation, of which 3 varieties are considered to be over-evaluated, 2 for the approval of supplement, and Jiangxi Yamagla Pharmaceuticals toluene sulfonate Sorabeni tablets for the domestic first imitation, the details are as follows: This week's consistency evaluation of the details of the table of hydrochloric acid citrate is the first 3-ketone acetyl coenzyme A sulfurase (3-KAT) inhibitor metabolic preparation, as an added drug for the first-line anti-angina treatment control is poor or intolerable stable angina adult patients.
original research enterprises for Schweia, the earliest listed in France, In 2000 China was approved for import.
According to medicinal data, China's existing hydrochloric acid quamide tablet market approval 10, including the original research enterprises, involving 10 manufacturers;
To date, the accumulation of hydrochloric acid Qumeta tablets has been through the consistency evaluation of five, namely, Zhangzhou Dongle Pharmaceuticals, Ruiyang Pharmaceuticals, Yuan da Pharma, Beijing Wansheng, Jiangsu Wu Zhong, Suzhou Pharmaceutical Factory.
pyridoxone metformin tablet pyrethroid tablets pyrethroid tablets (ryeton) are a compound preparation consisting of pyrethroidone and metformin for the treatment of type 2 diabetes.
According to pharmaceutical intelligence data, China now has only Jiangsu Deyuan Pharmaceuticals and Hangzhou Sino-American East China Pharmaceuticals two enterprises have the compound preparation market approval, the Chinese Pharmaceutical Society sample hospital data (CPA data) shows: in 2019 the overall sales of the domestic pyridoxone metformin sample hospital about 9016 Million yuan, Jiangsu Deyuan Pharmaceuticals this product sample market accounted for 6.79 percent, the first quarter of 2020 domestic pyridoxone metformin sample hospital total sales of about 22.79 million yuan, Jiangsu Deyuan Pharmaceutical "Fu Ruiyu" sample market accounted for 8.84 percent.
market sales and proportion of sample markets are on the rise.
according to the consistency evaluation progress database of drug intelligence network, Jiangsu Deyuan Pharmaceuticals was the first to improve the market competitiveness of the drug through consistency evaluation, laying a solid foundation for its future sales growth.
acid sedina non-tablets acid sedina non-tablets are type 5 phosphate esterase (PDE-5) inhibitors used to treat lung hypertension in adults with rare diseases (PAH, WHO Group 1) to improve motor capacity and delay clinical deterioration.
the original research company of Sidinafi was Pfizer, which was approved by the FDA on March 27, 1998, becoming the first ED-treated phosphate-5 (PDE-5) inhibitor to be used as a first-line drug for ED.
, china's urban retail pharmacy terminal, has sales of more than 2.3 billion yuan in 2019, with Baiyunshan accounting for the largest market share, followed by Pfizer, a former research firm, according to public data from The Network.
So far, there are 13 non-tablet domestic market approvals, manufacturers 7, of which 3 enterprises have passed the consistency evaluation of 3 products, this week Qilu Pharmaceuticals this variety according to the new drug 4 categories of registration approved, as the same as the evaluation, to the 2 billion level of anti-ED market challenge.
acid Westin that non-tablet consistency evaluation of the details of the table is also worth mentioning is the sour Westina non-tablet for the third batch of collection catalog drugs, Qilu Pharmaceuticals in the upcoming opening of the bid, was approved for listing, came sooner than just happened, just hitched the third batch of the ride, forming a 3-1 bidding pattern.
toluene sulfonate sorafini tablet sorafini is an oral multi-target, multi-kinase inhibitor.
is mainly used in the treatment of hepatocellular carcinoma, kidney cell carcinoma and thyroid cancer.
Sorafini, developed by Bayer, was approved for listing by the FDA in December 2005, approved in China in August 2006, included in the Category B list through national negotiations in 2017 and successfully renewed in 2019.
, the domestic medical insurance payment standard is 95 yuan / piece.
It is understood that in 2019, Sorafini domestic sales of about 1.2 billion yuan, of which the sample hospital sales reached 660 million yuan, so far the domestic toluene sulfonate Sorafini tablets declared listed only 4 enterprises, Yamagto Pharmaceuticals, won the first imitation at the same time as through consistency evaluation, breaking the barriers of original research.
Toluene Sulfonate Sorafini tablets reporting details table lists the sulphate-controlled release tablet Glipine is a sulfonate-based anti-sugar drug developed by Pfizer;
According to drug intelligence data, of which only Zibo Wanjie Pharmaceuticals, Beijing Honglin Pharmaceuticals, Changzhou Four Pharmaceuticals Pharmaceuticals, and just approved Nanjing Yiheng Pharmaceuticals 4 domestic enterprises were approved for production.
2019, the sales of Gretium controlled release tablet sample hospitals were 120 million yuan, of which Pfizer accounted for the vast majority of the share, amounting to 89.41 percent.
is now in addition to Nanjing Yiheng Pharmaceutical's first as through the consistency evaluation, no other enterprises have been evaluated, whether this opportunity to seize the share of the original research, it remains to be seen.
the declaration accepted 13 varieties were undertaken, Hengrui core first imitation agent was accepted this week CDE new consistency evaluation acceptance number 20 (13 varieties), injection again eye-catching, there are 8 varieties declared consistency evaluation was undertaken, Hengrui, Beet, stone medicine Sinono, Luoxin and other well-known enterprises in the heavy-weight products are listed.
This week's consistency evaluation declaration acceptance details note: red label for this week's first declared acceptance varieties which are worth mentioning is Hengrui Medicine's iodine keshaol injection, iodized keshaol injection is X-ray contrast agent, mainly used for adult cardiovascular imaging, cerebroan angioscopy, peri-arterial angiation, abdominal angiology, urinary tract imaging, intravenous imaging and CT enhancement examination, cardiovascular imaging in children.
Hengrui Pharmaceutical iodized keshaol injection is the first imitation product in China, and is one of the core imager products of Hengrui Pharmaceutical, china Pharmaceutical Industry Information Center data show that in 2019 the domestic iodized keshaol market size of 4,971 million yuan, accounting for 35.65 percent of the overall imager market share.
according to the enterprise announcement, in 2019 Hengrui imager achieved revenue of 3.23 billion yuan, an increase of nearly 39% year-on-year, the domestic imager market share of the first.
Previously, Hengrui pharmaceutical iodine keshaol injection has 2 acceptance number declaration consistency evaluation of one of the processing status is "sent" state, and now another acceptance number is accepted, can again on the basis of the first imitation through consistency evaluation, consolidate the first imitation status, access to a larger imager market cake, can be pending.
iodine keshaol injection consistent evaluation report acceptance details table data source: drug intelligence data, enterprise announcements and other network open data sources: drug intelligence network, enterprise announcements and other network open information.